Vioxx Cardiovascular Safety Raised Concerns During Original NDA Review

The need for additional studies to address the question of Vioxx’ cardiovascular safety was outlined in original review documents. Medical reviewers said it was difficult to reach meaningful conclusions with a relatively small number of events, as well as varying dosage levels and exposure times.